Medical artificial intelligence (AI) corporation Lunit announced on the 2nd that it will exclusively supply its AI solution to the breast cancer screening program operated by the State Government of Valencia, Spain.
Valencia, with a population of about 5 million, is the third largest municipality in Spain by population and the fourth largest by economic scale. Since last year, it has been considering the introduction of AI into the breast cancer screening program. Numerous global medical AI corporations participated in the bidding for this project, and Valencia selected Lunit as the final contractor after a comprehensive evaluation.
Under the supply contract, the breast cancer screening operated by Valencia will introduce the mammography AI 'Lunit Insight MMG' and the three-dimensional breast tomosynthesis AI 'Lunit Insight DBT.' The company did not disclose the scale of the contract amount.
With this contract, Valencia aims to expand the annual screening target from the current 250,000 to 400,000 while maintaining the quality of medical services. Lunit and Valencia intend to explore strategies for early cancer detection and improving health outcomes in the population through ongoing research collaboration in addition to the supply contract.
Seo Beom-seok, Lunit's CEO, said, "This contract is an important milestone for Lunit in being recognized in the European public healthcare market and will serve as a turning point for AI to establish itself as an essential cancer screening tool. The partnership with Valencia will significantly help in spreading across Europe in the future."
With its entry into Spain, Lunit has further strengthened its position in the global national cancer screening market (B2G). It currently operates public cancer screening programs in major countries, including Australia, Europe (Iceland, Spain), the Middle East (Saudi Arabia, Qatar, UAE), and Asia (Singapore), and is expanding its presence in the global market.